Physician profile
Clark Zhang
NPI 1679034326
$1,564.23
in general payments reported to CMS, 2019-2025
16 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $501.06 | 2025 | Tremfya |
| Abbvie INC. | $296.47 | 2025 | |
| Madrigal Pharmaceuticals | $192.45 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $124.99 | 2025 | Terlivaz |
| Qol Medical, LLC | $49.10 | 2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $43.78 | 2025 | Entyvio |
| Gilead Sciences, INC. | $32.12 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.01 | 2025 | Xifaxan |
| Ardelyx, INC. | $29.64 | 2025 | Ibsrela |
| Genzyme Corporation | $29.34 | 2025 | |
| Pfizer INC. | $24.83 | 2025 | |
| Intercept Pharmaceuticals, INC. | $22.08 | 2025 | |
| Aimmune Therapeutics, INC. | $21.22 | 2025 | Zenpep |
| Celltrion USA INC. | $20.25 | 2025 | Vegzelma |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.90 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.